Business
Resverlogix Completes Patient Recruitment for ASSERT Trial
Resverlogix Completes Patient Recruitment for ASSERT Trial
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nFeb. 8, 2010 (Canada NewsWire Group) -- CALGARY, Feb. 8 /CNW/ -- Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. \"The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic. At this rate we could be seeing the final dosed patient in May of 2010. In the second half of 2010, we look forward to being able to share the results from the trial, which will mark yet another major milestone in the development of our oral therapeutic for the treatment of atherosclerosis,\" explained Donald J. McCaffrey, President and CEO of Resverlogix Corp.Once completed, the randomized, double-blind, placebo-controlled, multi-centered US study will have administered RVX-208 to approximately 280 patients with stable coronary artery disease for a period of 13 weeks. The primary objective of this study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-l) levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time as well as to examine key reverse cholesterol markers involved with HDL functionality.In other news today, Donald J. McCaffrey will be providing an updated corporate overview during the BIO CEO & Investor conference. Mr. McCaffrey's presentation will take place in the Basildon room at the Waldorf-Astoria, New York City, from 4:00 pm - 4:25 pm EST.A link to this presentation can be found at:http://www.veracast.com/webcasts/bio/ceoinvestor2010/97114448.cfmThe webcast replay will be available one hour after conclusion of the live presentation and will be made available until May 11, 2010 at www.resverlogix.com.About RVX-208RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be a promising emerging drug for the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule currently undergoing clinical trials that is specifically designed to increase ApoA-I production, thereby raising HDL levels which ar...